Nature Reviews Clinical Oncology, Published online: 13 April 2026; doi:10.1038/s41571-026-01148-9 Patients with meningioma, the most common type of intracranial primary tumour, have been traditionally managed with surgery and radiotherapy, although advances over the past decade have brought about promising novel treatment options. In addition, new molecularly driven classification tools can improve prognostic accuracy and guide personalized management decisions. The authors of this Review provide an integrated roadmap for meningioma care as well as a framework for ongoing and future research in this field.
Nature Reviews Clinical Oncology, Published online: 13 April 2026; doi:10.1038/s41571-026-01148-9 Patients with meningioma, the most common type of intracranial primary tumour, have been traditionally managed with surgery and radiotherapy, although advances over the past decade have brought about promising novel treatment options. In addition, new molecularly driven classification tools can improve prognostic accuracy and guide personalized management decisions. The authors of this Review provide an integrated roadmap for meningioma care as well as a framework for ongoing and future research in this field.